Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ....

10 Jun 2024
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
AbbVie (ABBV:NYSE), 0 | AbbVie, Inc. (ABBV:NYS), 0 | Amneal Pharmaceuticals Inc (AMRX:NYSE), 0 | Amneal Pharmaceuticals, Inc. Class A (AMRX:NAS), 0 | BIOGEN (BIIB:NYSE), 0 | Biogen Inc. (BIIB:NAS), 0 | BRAINSTORM CELL THERAPEUTICS (BCLI:NYSE), 0 | Brainstorm Cell Therapeutics Inc. (BCLI:NAS), 0 | Bristol-Myers Squibb Co (BMY:NYSE), 0 | Bristol-Myers Squibb Company (BMY:NYS), 0 | Cytokinetics, Incorporated (CYTK:NAS), 0 | Eisai Co., Ltd. (4523:TKS), 0 | Roche Holding (ROG:VTX), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | GILEAD SCIENCES (GILD:NYSE), 0 | Gilead Sciences, Inc. (GILD:NAS), 0 | Ionis Pharmaceuticals, Inc. (IONS:NAS), 0 | Johnson & Johnson (JNJ:NYSE), 0 | Johnson & Johnson (JNJ:NYS), 0 | Merck & Co (MRK:NYSE), 0 | Merck & Co., Inc. (MRK:NYS), 0 | Novartis AG (NOT:ETR), 0 | Pfizer Inc (PFE:NYSE), 0 | Pfizer Inc. (PFE:NYS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Teva Pharmaceutical Industries Limited (TEVA:TAE), 0 | uniQure N.V. (QURE:NAS), 0 | Wave Life Sciences Ltd. (WVE:NAS), 0 | Ionis Pharmaceuticals, Inc. (0JDI:LON), 0 | uniQure N.V. (0EE0:LON), 0

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
AbbVie (ABBV:NYSE), 0 | AbbVie, Inc. (ABBV:NYS), 0 | Amneal Pharmaceuticals Inc (AMRX:NYSE), 0 | Amneal Pharmaceuticals, Inc. Class A (AMRX:NAS), 0 | BIOGEN (BIIB:NYSE), 0 | Biogen Inc. (BIIB:NAS), 0 | BRAINSTORM CELL THERAPEUTICS (BCLI:NYSE), 0 | Brainstorm Cell Therapeutics Inc. (BCLI:NAS), 0 | Bristol-Myers Squibb Co (BMY:NYSE), 0 | Bristol-Myers Squibb Company (BMY:NYS), 0 | Cytokinetics, Incorporated (CYTK:NAS), 0 | Eisai Co., Ltd. (4523:TKS), 0 | Roche Holding (ROG:VTX), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | GILEAD SCIENCES (GILD:NYSE), 0 | Gilead Sciences, Inc. (GILD:NAS), 0 | Ionis Pharmaceuticals, Inc. (IONS:NAS), 0 | Johnson & Johnson (JNJ:NYSE), 0 | Johnson & Johnson (JNJ:NYS), 0 | Merck & Co (MRK:NYSE), 0 | Merck & Co., Inc. (MRK:NYS), 0 | Novartis AG (NOT:ETR), 0 | Pfizer Inc (PFE:NYSE), 0 | Pfizer Inc. (PFE:NYS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Teva Pharmaceutical Industries Limited (TEVA:TAE), 0 | uniQure N.V. (QURE:NAS), 0 | Wave Life Sciences Ltd. (WVE:NAS), 0 | Ionis Pharmaceuticals, Inc. (0JDI:LON), 0 | uniQure N.V. (0EE0:LON), 0
- Published:
10 Jun 2024 -
Author:
Research Team ACF -
Pages:
40 -
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ....